Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
Stereotactic Body Radiotherapy vs Sorafenib Alone...
Journal article

Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma

Abstract

Importance: Most patients with locally advanced hepatocellular carcinoma (HCC) recur within the liver following systemic therapy. Objective: To determine whether stereotactic body radiation therapy (SBRT) improves outcomes in patients with locally advanced HCC compared with sorafenib alone.

Authors

Dawson LA; Winter KA; Knox JJ; Zhu AX; Krishnan S; Guha C; Kachnic LA; Gillin MT; Hong TS; Craig TD

Journal

JAMA Oncology, Vol. 11, No. 2, pp. 136–144

Publisher

American Medical Association (AMA)

Publication Date

February 1, 2025

DOI

10.1001/jamaoncol.2024.5403

ISSN

2374-2437